| TECHNOLOGY
Driving Down Launch Costs and Timing with EPC Edge Therapeutics, a young biotech, finds a better way to get ready for launch By Justin Zamirowski, Senior Director, Operational Excellence, Edge Therapeutics
In 2015, 29 new drugs were launched in the U.S. and all of them experienced some delay, ranging from 5 to 87 days with the average at 45 days delay. The price of such massive delays in today’s competitive marketplace can be, on average, $1 million per day, which is unacceptable. Now, with more pressure to bring down drug prices, life sciences companies need to plug the holes of leaky processes. Many are turning to modern cloud-based technologies but few are considering the role that improved project management can play in making a real difference in time to market. Project management plays a much bigger role in other industries, with many Fortune 500 companies creating entire centralized Project Offices equipped with enterprise software to run nearly every complex project at the company. However, there is not as much emphasis in the life sciences industry, for a range of reasons. Yet, there’s no more time left to be inefficient or rest on old processes. Real change is needed, and it’s coming in the form of enterprise project collaboration (EPC) software. EPC software can improve visibility and increase the efficiency of decision-making so life sciences companies can finally eliminate their delays to market. -Editor
65 | HS&M AUGUST/SEPTEMBER 2017
Edge Therapeutics is a clinical-stage biotechnology company founded in 2009 and based in New Jersey. The company’s lead product candidate, EG-1962, is in Phase 3 clinical study and has the potential to improve clinical outcomes over the current standard of care for patients experiencing a ruptured brain aneurysm. The product utilizes Edge’s proprietary delivery system that seeks to enable targeted and sustained drug exposure at the site of injury while potentially avoiding off-target side effects. While still the Senior Director of Commercial Operations at Otsuka, I was invited to join this very exciting and fast growing organization to lead the crucial stages of late stage development, portfolio management,
